Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364958 | 0.87 | AAK1 (0.36) | AAK1LIPGALOX5 | |
| SCHEMBL30470940 | 0.87 | AAK1 (0.36) | AAK1LIPGALOX5 | |
| SCHEMBL30469929 | 0.84 | AAK1 (0.36) | AAK1LIPGLOXL2 | |
| SCHEMBL24365042 | 0.84 | AAK1 (0.36) | AAK1LIPGLOXL2 | |
| SCHEMBL24233998 | 0.84 | AAK1 (0.36) | AAK1LIPGLOXL2 | |
| SCHEMBL29980678 | 0.83 | AAK1 (0.35) | AAK1LOXL2 | |
| SCHEMBL24364315 | 0.83 | PIK3CA (0.48) | NOS3NOS1NOS2PIK3CDPIK3CA | |
| SCHEMBL30469738 | 0.83 | PIK3CA (0.48) | NOS3NOS1NOS2PIK3CDPIK3CA | |
| SCHEMBL31136351 | 0.82 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL24363782 | 0.82 | SMN1; SMN2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | AAK1 4778/4885LIPG 2618/4885NOS3 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.